LYNN SAGE BREAST CANCER SYMPOSIUM
SEPTEMBER 7 – 10, 2023
Chicago Marriott Downtown Magnificent Mile

SYMPOSIUM CHAIR
William Gradishar, MD

SYMPOSIUM CO-CHAIR
Monica Morrow, MD

SCIENTIFIC PLANNING COMMITTEE
Nora Hansen, MD
Kalliopi Siziopikou, MD, PhD
Jonathan Strauss, MD, MBA

VISIT OUR WEBSITE
lynnsagebreastcancer.org
Referred to as the most valuable breast cancer meeting worldwide for the practicing clinician, the Lynn Sage Breast Cancer Symposium will provide 3.5 days of in-person presentations and interactive Q&A sessions.

For 25 years, this multidisciplinary CME program has provided the latest information regarding cutting-edge technology and approaches in the management of breast cancer from leading national and international medical, surgical, and radiation oncologists. This year’s symposium will include a superb line-up of internationally recognized faculty who will present the latest research findings and be available for interaction following their presentations. The symposium will focus on the close cooperation required for effective multidisciplinary management of patients with breast cancer.

Educational Objectives

1. Describe toxicities of breast cancer treatment, including financial toxicity
2. Cite management issues for local and systemic therapy particular to young women with breast cancer
3. Determine appropriate tailoring of surgery and radiotherapy after neoadjuvant systemic therapy
4. Discuss current approaches to systemic therapy in the adjuvant and neoadjuvant settings for HER2+ breast cancer
5. Recognize the controversies surrounding universal genetic testing
6. Restate the management issues for pregnant patients with early stage breast cancer
7. Explain the new treatment options for patients with metastatic triple negative breast cancer
8. Interpret the management issues related to uncommon histologic subtypes of breast cancer
9. Identify optimal duration and composition of adjuvant endocrine therapy in high risk patients
10. Distinguish HER2 low breast cancer in terms of distinct features and treatment options
11. Summarize different radiation therapy schedules and appropriate clinical settings for each

Target Audience
The target audience for this activity includes medical oncologists, radiation oncologists, surgical oncologists, fellows in training, oncology nurses, and allied health professionals in breast cancer.

Lynn Sage Symposium Travel Awards Program: If you have fellows from your institution who may be interested in attending the symposium, please share the following with them:

The Lurie Cancer Center invites fellows and residents to apply for the Lynn Sage Symposium Travel Awards Program. The program is an annual opportunity for residents and fellows to ascertain the latest clinical and scientific advances in breast cancer research through their attendance at the symposium and to meet breast cancer experts from around the world.

In addition to attending the symposium, the awardees will participate in a forum to discuss case studies contrasting the differences or similarities in the management of patients with various breast cancer disease states. Additionally, physicians from both the academic and private practice settings will present their experiences, recommendations, and guidance on the career paths available to residents and fellows.

Detailed information is available online at: [http://www.lynnsagebreastcancer.org/scholars.cfm](http://www.lynnsagebreastcancer.org/scholars.cfm).

Fellows from the Chicago area are invited to apply for the scholars program and, if selected, they will get their registration fee waived and complimentary parking (no hotel accommodations).
Session 1: Toxicities and Breast Cancer
Moderator: Nora Hansen, MD

9:00 am
Welcome
William Gradishar, MD

9:05 am
Skin Toxicity
Mario Lacouture, MD

9:35 am
Reconstructive Options and What Patients Want
Jonas Nelson, MD, MPH

10:05 am
Diet, Microbiome and Breast Cancer
Leah Ferrucii, PhD, MPH

10:35 am
Quality of Life - Fertility, Sex or Pain Management
Tara Sanft, MD

11:05 am
Financial Toxicity
Fumiko Chino, MD

11:35 am
Q & A

11:55 am
Lunch & Exhibits

Session 2: Pathology for the Non-Pathologist
Moderator: Kalliopi Siziopikou, MD, PhD

1:00 pm
Metaplastic Carcinoma of the Breast
Celina Kleer, MD

1:30 pm
Updates in Breast Cancer Biomarker Testing
Xiaoxian (Bill) Li, MD, PhD

2:00 pm
Evaluation of Axillary Lymph Nodes in Breast Cancer
Julie Jorns, MD

2:30 pm
The Informative Breast Pathology Report
Kalliopi Siziopikou, MD, PhD

3:00 pm
Q & A

3:20 pm
Break

3:40 pm
Unusual Cases
William Gradishar, MD

4:40 pm
Award Ceremony

5:10 pm
Adjourn
Session 3: Imaging and Risk  
Moderator: Seema Khan, MD

8:30 am  
Pros and Cons of Universal Genetic Testing for Breast Cancer Patients  
Claudine Isaacs, MD

9:00 am  
What’s on the Horizon for Risk Reduction?  
Melissa Pilewskie, MD

9:30 am  
Pathology of High Risk Lesions: Have We Learned Anything New?  
Stuart Schnitt, MD

10:00 am  
Break

10:20 am  
Controversies in Imaging  
Maxine Jochelson, MD

11:10 am  
LYNN SAGE LECTURE  
The Evolving Paradigm of the Local Therapy of Breast Cancer: Are We Getting It Right?  
Monica Morrow, MD

12:10 pm  
Lunch

Session 4: Hormone Receptor Positive Cancer and Young Women  
Moderator: William Gradishar, MD

1:30 pm  
Pregnancy and Breast Cancer  
Ann Partridge, MD, MPH

2:00 pm  
Surgical Issues in Young Women with Breast Cancer  
Tari King, MD

2:30 pm  
Controversies in Adjuvant Endocrine Therapy in Premenopausal Women  
Ruth O’Regan, MD

3:00 pm  
Break

3:20 pm  
Eliminating Radiation Therapy in HR+ Cancer: Where Are We?  
Lior Braunstein, MD

3:50 pm  
Options in Endocrine Therapy and Beyond for Metastatic Disease  
Virginia Kaklamani, MD

4:20 pm  
Q & A

4:45 pm  
Adjourn
Session 5: Evolving Areas in Management
Moderator: Swati Kulkarni, MD

8:30 am
Update on Systemic Therapy for Triple Negative Cancer
Rita Nanda, MD

9:00 am
Nipple Sparing Mastectomy: Where Are We Now?
Armando Giuliano, MD

9:30 am
Update on Genomic Testing in HR+ Breast Cancer
Kevin Kalinsky, MD, MS

10:00 am
Oncoplastic Breast Surgery 2023
Walter Paul Weber, MD

10:30 am
Break

11:00 am
Tailoring Surgery for Uncommon Histologic Types
George Plitas, MD

11:30 am
Q & A

12:00 pm
Lunch

Session 6: Unresolved Problems
Moderator: Monica Morrow, MD

1:15 pm
HER2 Low Now and in the Future
Shanu Modi, MD

1:45 pm
Management of Brain Metastases
Sarah Sammons, MD

2:15 pm
Inflammatory Breast Cancer: Different or Just Part of a Continuum?
Hal Burstein, MD, PhD

2:45 pm
Patient Reported Outcomes in Breast Cancer
Audree Tadros, MD

3:15 pm
Q & A

3:45 pm
Case Management Panel
Monica Morrow, MD

Panelists:
William Gradishar, MD
Nora Hansen, MD
Jonathan Strauss, MD
Shanu Modi, MD

5:00 pm
Adjourn
Session 7: Issues in Neoadjuvant Therapy
Moderator: Jonathan Strauss, MD, MBA

8:30 am
Surgery of the Breast after Neoadjuvant Chemotherapy
Andrea Barrio, MD

9:00 am
Optimizing Axillary Staging after Neoadjuvant Chemotherapy
Giacomo Montagna, MD, MPH

9:30 am
New Approaches to Residual Tumor after Neoadjuvant Chemotherapy
William Gradishar, MD

10:00 am
Tailoring Radiation Therapy to Response: Standard Practice?
Jonathan Strauss, MD, MBA

10:30 am
Q & A

11:00 am
Adjourn

Registration
Advance registration is encouraged, as space and program materials are limited. The registration fee includes conference tuition, CME credits, MOC points, access to digital materials and networking opportunities. Register online at lynnsagebreastcancer.org.

<table>
<thead>
<tr>
<th>Type</th>
<th>Discounted Through August 1</th>
<th>Regular After August 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>General</td>
<td>$675</td>
<td>$775</td>
</tr>
<tr>
<td>Fellow/Student/Trainee</td>
<td>$375</td>
<td>$475</td>
</tr>
<tr>
<td>Nurse/Physician Assistant/Nurse Practitioner</td>
<td>$375</td>
<td>$475</td>
</tr>
<tr>
<td>Industry Representative</td>
<td>$875</td>
<td>$975</td>
</tr>
</tbody>
</table>

ADDITIONAL FEES
Lunch Ticket (no refunds) $40/day

Refund/Cancellation Policy
Registration fees, less a $50 administrative handling fee, are refundable if written request is received on or before August 1, 2023. Please include your registration ID number when requesting a refund. No refunds will be granted after August 1, 2023. However, you may transfer your registration to a colleague. For further information, please call 312-503-7809 or email cancer@northwestern.edu.
<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrea Barrio, MD, FACS</td>
<td>Memorial Sloan Kettering Cancer Center</td>
</tr>
<tr>
<td>Lior Braunstein, MD</td>
<td>Memorial Sloan Kettering Cancer Center</td>
</tr>
<tr>
<td>Hal Burstein, MD, PhD</td>
<td>Dana-Farber Cancer Institute</td>
</tr>
<tr>
<td>Fumiko Chino, MD</td>
<td>Memorial Sloan Kettering Cancer Center</td>
</tr>
<tr>
<td>Leah Ferruci, PhD, MPH</td>
<td>Yale School of Public Health</td>
</tr>
<tr>
<td>Armando Giuliano, MD</td>
<td>Cedars-Sinai Medical Center</td>
</tr>
<tr>
<td>William Gradishar, MD</td>
<td>Robert H. Lurie Comprehensive Cancer Center of Northwestern University</td>
</tr>
<tr>
<td>Nora Hansen, MD</td>
<td>Robert H. Lurie Comprehensive Cancer Center of Northwestern University</td>
</tr>
<tr>
<td>Claudine Isaacs, MD</td>
<td>Lombardi Comprehensive Cancer Center at Georgetown University</td>
</tr>
<tr>
<td>Maxine Jochelson, MD</td>
<td>Memorial Sloan Kettering Cancer Center</td>
</tr>
<tr>
<td>Julie Jorns, MD</td>
<td>Medical College of Wisconsin</td>
</tr>
<tr>
<td>Virginia Kaklamani, MD</td>
<td>UT Health San Antonio</td>
</tr>
<tr>
<td>Kevin Kalinsky, MD, MS</td>
<td>Winship Cancer Institute</td>
</tr>
<tr>
<td>Tari King, MD</td>
<td>Dana-Farber Cancer Institute/Brigham Cancer Center</td>
</tr>
<tr>
<td>Celina Kleer, MD</td>
<td>University of Michigan</td>
</tr>
<tr>
<td>Mario Lacouture, MD</td>
<td>Memorial Sloan Kettering Cancer Center</td>
</tr>
<tr>
<td>Xiaoxian (Bill) Li, MD, PhD</td>
<td>Emory University</td>
</tr>
<tr>
<td>Shana Modi, MD</td>
<td>Memorial Sloan Kettering Cancer Center</td>
</tr>
<tr>
<td>Giacomo Montagna, MD, MPH</td>
<td>Memorial Sloan Kettering Cancer Center</td>
</tr>
<tr>
<td>Monica Morrow, MD</td>
<td>Memorial Sloan Kettering Cancer Center</td>
</tr>
<tr>
<td>Rita Nanda, MD</td>
<td>University of Chicago Medicine</td>
</tr>
<tr>
<td>Jonas Nelson, MD, MPH</td>
<td>Memorial Sloan Kettering Cancer Center</td>
</tr>
<tr>
<td>Ruth O'Regan, MD</td>
<td>University of Rochester Medical Center</td>
</tr>
<tr>
<td>Ann Partridge, MD, MPH</td>
<td>Dana-Farber Cancer Institute</td>
</tr>
<tr>
<td>Melissa Pilewskie, MD</td>
<td>Rogel Cancer Center, University of Michigan Health</td>
</tr>
<tr>
<td>George Pilias, MD</td>
<td>Memorial Sloan Kettering Cancer Center</td>
</tr>
<tr>
<td>Sarah Sammons, MD</td>
<td>Dana-Farber Cancer Institute</td>
</tr>
<tr>
<td>Tara Sanft, MD</td>
<td>Yale School of Medicine</td>
</tr>
<tr>
<td>Stuart Schnitt, MD</td>
<td>Dana-Farber Cancer Institute/Brigham and Women's Hospital</td>
</tr>
<tr>
<td>Kalliopi Siziopikou, MD, PhD</td>
<td>Robert H. Lurie Comprehensive Cancer Center of Northwestern University</td>
</tr>
<tr>
<td>Jonathan Strauss, MD, MBA</td>
<td>Robert H. Lurie Comprehensive Cancer Center of Northwestern University</td>
</tr>
<tr>
<td>Audree Tadros, MD</td>
<td>Memorial Sloan Kettering Cancer Center</td>
</tr>
<tr>
<td>Walter Paul Weber, MD</td>
<td>University Hospital Basel</td>
</tr>
</tbody>
</table>

**Faculty Disclosure**

Northwestern University Feinberg School of Medicine requires course directors, speakers, instructors, planners and other individuals who are in a position to control the content of this activity to disclose any relevant financial relationships. All identified potential conflicts of interest, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations are thoroughly vetted by Northwestern University FSM for fair balance. The faculty disclosures will be indicated at the symposium.
Accreditation Statement
The Northwestern University Feinberg School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
The Northwestern University Feinberg School of Medicine designates this live activity for a maximum of 22.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Surgery Accredited CME and Self-Assessment
Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME and Self-Assessment requirements of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.

Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 22.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For additional information or to register, visit lynnsagebreastcancer.org or call 312-503-7809.